|Position||Trades||Duration||Win rate||Win/loss||Avg win||Avg loss||Return|
|Position||Trades||Duration||Win Rate||Win/Loss||Avg Win||Avg Loss||Return|
Trading: SELL @ $0.092
Signal Strength: WEAK
Indicator MUST BE USED in additional to another technical indicator to confirmation for trading entry. Indicator can be applied to the short term timeframe but is only able to give and indication of the strength of the buyers versus sellers at the market close. This bar analysis can provide guidance on the daily battle between sellers and buyers from the companies recent trading.
Impedimed (ASX:IPD) sellers are increasingly eager. This is the first day sellers have increasing eagerness for IPD adding strength to a downtrend in the first timeframe. The biggest price range this month has been $0.0540 & the greatest daily price range this year has been $0.0890. The price range ratio this week versus the quarterly price range is 0.4x & the price range ratio this month versus the year to date price range is 0.6x.
The range of the bar gives important information about the strength of weakness of a trend. If buyers are very committed they will be keen to buy and will tend to bid the price up even in the face of some selling pressure. Price will quickly & easily move upward and the move will tend to be significant. As such expanding ranges indicate the either buyers or sellers becoming more committed. Alternatively once the range begins to contract the side in control are losing commitment.
Calculation: Range Today Versus Range Yesterday (RTRY):
1) Expanding ranges on the upside indicates that buyers are increasingly eager;
2) Expanding ranges on the downside indicates that sellers are increasingly eager;
3) Contracting ranges on the upside indicates that buyers are becoming less eager;
4) Contracting ranges on the downside indicates that sellers are becoming less eager;
PROFILE: Impedimed (IPD.AX)
Stock Exchange: ASX
Ticker Codes: | IPD.AX | ASX:IPD |
ImpediMed Limited, together with its subsidiaries, engages in the development, manufacture, and sale of bioimpedance devices and consumables in Australia, North America, Europe, and internationally. The company operates through Medical and Test & Measurement segments. It offers L-Dex U400, a technology that utilizes the characteristics of frequency dependent current flow to quantify changes in extracellular fluid in the patient's limb; and SFB7, a tetra polar bioimpedance spectroscopy device that scans various frequencies for the estimation of body composition in healthy individuals. The company also provides DF50, a single frequency body composition analysis in healthy individuals; and ImpediVET, a bioimpedance spectroscopy technology for use in veterinary applications. Its products are used in a range of applications, such as in the assessment and monitoring of secondary lymphedema, as well as monitoring of body composition and hydration. In addition, the company is involved in the supply of power precision testing and measuring equipment. ImpediMed Limited was founded in 1999 and is headquartered in Pinkenba, Australia.
|ALK Alkane Exploration||0.91||6.5||4,762,492||-1||BEARISH|
|LNG Liquefied Natural Gas||0.12||4.5||831,546||-1||BEARISH|
|MNF My Net Fone||4.16||2.7||763,939||0||BEARISH|
|FOR Forager Australian Shares||1.12||2.3||463,174||0||BEARISH|
|RRL Regis Resources||4.43||1.6||4,267,655||0||BEARISH|
|OGC Oceanagold Corporation||2.75||1.5||369,282||0||BEARISH|
|PIC Perpetual Equity Investment||1.02||1.5||398,609||0||BEARISH|